Publications by authors named "C Ogura"

Article Synopsis
  • Palbociclib (PAL) is a targeted therapy for estrogen receptor-positive and HER2-negative recurrent breast cancer, often used alongside other endocrine treatments.
  • A study found that patients with higher levels of white blood cells (WBC), neutrophils (Neu), and lymphocytes (Lym) experienced longer treatment durations when on PAL, suggesting these blood cell counts could influence treatment success.
  • The median time-to-treatment failure (TTF) was 5.6 months, with differences noted between groups receiving fulvestrant (FUL) and aromatase inhibitors (AI), though not all differences were statistically significant, indicating more research is needed in this area.
View Article and Find Full Text PDF

Aims: Durvalumab (Durva) administration after chemoradiation therapy (CRT) in locally advanced non-small-cell lung cancer (NSCLC) is the standard of care, associated with relatively prolonged progression-free (PFS) and overall survival. However, pneumonitis occurs in 73.6% of Japanese patients.

View Article and Find Full Text PDF

Mouse embryonic stem cells (mESCs) have the properties of self-renewal and pluripotency. Various signals and growth factors maintain their undifferentiated state and also regulate their differentiation. Glycosaminoglycans are present on the cell surface and in the cell matrix as proteoglycans.

View Article and Find Full Text PDF

Mouse embryonic stem cell (ESC) pluripotency is tightly regulated by a complex network composed of extrinsic and intrinsic factors that allow proper organismal development. O-linked β-N-acetylglucosamine (O-GlcNAc) is the sole glycosylation mark found on cytoplasmic and nuclear proteins and plays a pivotal role in regulating fundamental cellular processes; however, its function in ESC pluripotency is still largely unexplored. Here, we identify O-GlcNAcylation of proteasome activator subunit 3 (Psme3) protein as a node of the ESC pluripotency network.

View Article and Find Full Text PDF

Embryonic stem cells (ESCs) and epiblast-like cells (EpiLCs) recapitulate in vitro the epiblast first cell lineage decision, allowing characterization of the molecular mechanisms underlying pluripotent state transition. Here, we performed a comprehensive and comparative analysis of total glycomes of mouse ESCs and EpiLCs, revealing that overall glycosylation undergoes dramatic changes from early stages of development. Remarkably, we showed for the first time the presence of a developmentally regulated network orchestrating glycosylation changes and identified polycomb repressive complex 2 (PRC2) as a key component involved in this process.

View Article and Find Full Text PDF